Advanced search
Start date

Study of polymorphism of small molecule tyrosine kinase inhibitors.

Grant number: 15/15456-5
Support type:Scholarships abroad - Research
Effective date (Start): February 01, 2016
Effective date (End): January 31, 2017
Field of knowledge:Health Sciences - Pharmacy - Medicines Analysis and Control
Principal researcher:Gabriel Lima Barros de Araujo
Grantee:Gabriel Lima Barros de Araujo
Host: Stephen R. Byrn
Home Institution: Faculdade de Ciências Farmacêuticas (FCF). Universidade de São Paulo (USP). São Paulo , SP, Brazil
Research place: Purdue University, United States  


Polymorphism can cause quality deviations during the production of medicines and can influence their effectiveness. Therefore, an understanding of this phenomenon and its implications opens a wide field of possibilities to be explored in the pharmaceutical field, including the emergence of new paradigms and tools for the quality assurance of medicines. Small molecule tyrosine kinase inhibitors (TKIs) represent an extremely promising and rapidly expanding group of antitumor drugs given orally. Although some polymorphism information of these compounds is included in the patents, the basic structural and thermodynamic data are poor in terms of quality of the measurements and differences and misconceptions between the crystals forms reported are evident. Additionally, polymorphism is an important factor that can impact the bioavailability and, consequently, clinical efficacy of those compounds, since most of them have low solubility in water. This project falls within this scope and focuses on: (i) preparation of polymorphs, solvates, or co-crystals of TKIs; (ii) their characterization in terms of structure and thermodynamic stability; (iii) their evaluation in terms of biopharmaceutical performance.

News published in Agência FAPESP Newsletter about the scholarship:
Articles published in other media outlets (0 total):
More itemsLess items

Scientific publications
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
DE ARAUJO, GABRIEL L. B.; ZELLER, MATTHIAS; SMITH, DANIEL; NIE, HAICHEN; BYRN, STEPHEN R.. Unexpected Single Crystal Growth Induced by a Wire and New Crystalline Structures of Lapatinib. Crystal Growth & Design, v. 16, n. 10, p. 6122-6130, . (15/15456-5, 15/05685-7)
ZELLER, MATTHIAS; BARROS DE ARAUJO, GABRIEL LIMA; PARKER, TREV; RAI, AMRINDER SINGH; BYRN, STEPHEN R.. A new solvate of afatinib, a specific inhibitor of the ErbB family of tyrosine kinases. ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS, v. 73, n. 3, p. 417+, . (15/05685-7, 15/15456-5)

Please report errors in scientific publications list by writing to: